March 17, 2020Management
AGC Decides to Launch Voluntary Tender Offer for Shares of Molmed
The VTO aims to obtain all of the issued shares of Molmed (463,450,672) at 0.518 Euros/share, amounting to 240 Million Euros if all of the shares are successfully acquired, and the subsequent delisting of the Issuer from the Italian Stock Exchange. This VTO is subject to certain conditions (e.g. the acceptances of the VTO of a number of shares representing not lower than 66.7% of the entire share capital), and is more fully described in the notice to the market issued in accordance with Italian law. Further details of the VTO will be contained in the offer document which will be published in the next few weeks.
Gene & cell therapy is an innovative therapeutic method, that aim to treat diseases that do not have adequate treatments to date. Approximately 1000 clinical trials are underway worldwide, and the market is expected to grow at a rapid rate. Molmed has strength especially in vectors and cells manufacturing backed by its robust production platform, also providing third party GMP manufacturing services of engineered cells and viral vectors for various companies from large biopharmaceuticals to biotech companies.
Notes:
*1) CDMO: Contract Development & Manufacturing Organization
REFERENCE
Established | 1996 |
Located | Milan, Italy |
Number of employees | App. 220 |
Revenue | 36.3 Million Euros (2019) |
Business Arena | Gene & Cell therapy Discovery, R&D, Manufacturing, Clinical Validation, Third Party GMP Services. |
Issued shares | 463,450,672 |
Website | https://www.molmed.com/en/node/1 |
■Where Molmed fits into AGC’s Business

- MEDIA INQUIRIES
- Kazumi Tamaki, General Manager, Corporate Communications & Investor Relations Division
AGC Inc. - Contact: Yuki Kitano
- TEL: +81-3-3218-5603
- E-mail: info-pr@agc.com